<DOC>
	<DOCNO>NCT02251873</DOCNO>
	<brief_summary>Study characterise effect concurrent tipranavir ( TPV ) ritonavir ( RTV ) administration single dose pharmacokinetics didanosine ( ddI ) , characterise effect single-dose ddI pharmacokinetics TPV RTV ass short-term safety combination</brief_summary>
	<brief_title>Evaluation Pharmacokinetic Interaction Steady State Tipranavir Ritonavir Tipranavir Ritonavir With Single Dose Didanosine Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<criteria>Healthy male female subject determine result screen Female subject lactate child bear potential define surgically sterile post menopausal ( period least 12 month elevate follicle stimulate hormone ( FSH ) low estradiol estrogen supplementation ) . Females use barrier contraception ( e.g . condom ) least one month prior administration study medication , study least one month release study . Women negative pregnancy test Signed write informed consent accordance Good Clinical Practice ( GCP ) local legislation Age &gt; =18 &lt; =60 year Body mass index ( BMI ) &gt; =18.5 &lt; =29.9 kg/m2 Any find medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance History current gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunologic , hormonal disorder , include clinical history viral hepatitis , serological evidence active Hepatitis B , Hepatitis C , HIV infection History orthostatic hypotension , faint spell blackouts Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator include study drug Intake drug long halflife ( &gt; 24 hour ) enzyme alter drug within 1 month prior administration study drug Use drug might influence result trial within 10 day prior administration trial ( addition specific medication prohibition mention exclusion criterion ) Use grapefruit grapefruit juice , alcohol , green tea , methylxanthinecontaining product tobacco within one week study drug administration Participation another trial investigational drug within 2 month prior administration trial Smoker ( &gt; 10 cigarette 3 cigar 3 pipes/day ) inability refrain smoke trial day Alcohol abuse ( &gt; 60 g/day ) Drug abuse Blood plasma donation within 1 month prior administration trial Excessive physical activity within 5 day prior administration trial Following specific laboratory finding : activate partial thromboplastin time ( aPTT ) , prothrombin time international normalise ratio ( INR ) , aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , gammaglutamyltransferase ( GGT ) , amylase , lipase , triglyceride normal range Any laboratory value outside clinically accept reference range clinical relevance History familial bleeding disorder Inability swallow multiple large capsule Inability comply dietary regimen study centre Inability comply investigator 's instruction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>